An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma

NCT06015321 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Prostatic Adenocarcinoma

Interventions

DRUG: Enzalutamide

Sponsor

Samsung Medical Center